Literature DB >> 1138394

Pathology of malignant melanoma of the skin in Black Africans.

J J Rippey, E Rippey, R M Giraud.   

Abstract

Follow-up data (over a 3-year period) and the histological appearances of primary lesion were studied and related in 40 Black patients with malignant melanoma. This to our knowledge is the first study in Black African patients. It was found that they present with large deeply invasive lesions, particularly on the foot. The prognosis is poor, with an over-all 3-year survival rate of 35%. The histological features used to assess the prognosis of malignant melanoma in Whites, that is histogenetic pattern, size and shape of the lesion, level of invasion, presence of ulceration and mitotic activity would seem to be equally applicable in Black patients. In addition, marked cellular pleomorphism, haemorrhage, necrosis and fibrosis within the tumour are bad signs. In this series lymphocytic infiltration, either within the tumour or at the edge, possibly indicative of an immune response, seemed to be of favourable prognostic import. Surprisingly, a lesion histologica-ly that of lentigo maligna melanoma was found on the feer of some blacks and could be related to much more favourable survival figures.

Entities:  

Mesh:

Year:  1975        PMID: 1138394

Source DB:  PubMed          Journal:  S Afr Med J


  2 in total

1.  Acral lentiginous melanoma. A clinicopathologic entity.

Authors:  E T Krementz; R J Feed; W P Coleman; C M Sutherland; R D Carter; M Campbell
Journal:  Ann Surg       Date:  1982-05       Impact factor: 12.969

Review 2.  Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease.

Authors:  Patricia Basurto-Lozada; Christian Molina-Aguilar; Carolina Castaneda-Garcia; Martha Estefania Vázquez-Cruz; Omar Isaac Garcia-Salinas; Alethia Álvarez-Cano; Héctor Martínez-Said; Rodrigo Roldán-Marín; David J Adams; Patricia A Possik; Carla Daniela Robles-Espinoza
Journal:  Pigment Cell Melanoma Res       Date:  2020-06-17       Impact factor: 4.693

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.